

**CARDIOLOGY UPDATE 2006**

## Migraine Headaches: The Immunologist's View

Theoharis C. Theoharides, Ph.D, M.D.

*Departments of <sup>1</sup>Pharmacology  
and Experimental Therapeutics,  
<sup>2</sup>Biochemistry, <sup>3</sup>Internal Medicine,  
Tufts University School of Medicine  
and Tufts – New England Medical  
Center, Boston, MA, USA*

**KEY WORDS:** *inflammation, mast cells,  
stress, vascular permeability*

### ABSTRACT

**OBJECTIVE:** Review evidence supporting the role of mast cells in migraine pathophysiology. **BACKGROUND:** Mast cells are known for their role in allergic reactions, but they are also important in immunity and inflammatory diseases, especially those precipitated or worsened by stress. Such are migraine headaches that are associated with spreading neuronal depression and neurogenic inflammation intracranially. Migraines are also comorbid with allergies and could precipitate acute coronary syndromes (ACS). Mast cells are located perivascularly, in close association with neurons, especially in the meninges. Mast cells can be activated by trigeminal nerve stimulation and by acute stress, leading to increased vascular permeability and neurogenic inflammation dependent on NK-1 receptors, but not necessarily on substance P (SP). **METHODS:** We reviewed relevant literature and summarized our own findings. **RESULTS:** Corticotropin-releasing hormone (CRH), a mediator of the stress response released from the hypothalamus, can activate CRH receptors either on the sensory nuclei of the trigeminal nerve or directly on the mast cells. They, then release proinflammatory, nociceptive and vasoactive mediators including histamine, tryptase and vascular endothelial growth factor (VEGF), thereby triggering migraine headaches. **CONCLUSIONS:** These results indicate that there are several novel points of intervention for the development of therapeutic agents to help alleviate migraines. Preliminary clinical studies with brain mast cell blockers and CRH receptor antagonists suggest that they could be useful prophylactically.

### 1. SELECTIVE RELEASE OF MAST CELL MEDIATORS

Mast cells derive from a distinct precursor in the bone marrow [1] and mature under local tissue microenvironmental factors [2]. Mast cells are necessary for the development of allergic reactions, through crosslinking of their surface receptors for IgE (FcεRI), leading to degranulation and the release of vasoactive, pro-inflammatory and nociceptive mediators that include histamine, cytokines and proteolytic enzymes [3,4] (Table 1). The multitude of mediators that could be secreted, especially in response to many non-immunologic triggers (Table 2) has given rise to new speculations about the possible role of mast cells in immune responses, especially acquired immunity and inflammation [6].

Unlike allergic reactions, mast cells are rarely seen to degranulate during autoim-

*Address for correspondence:*  
T.C. Theoharides, Ph.D., M.D.  
Department of Pharmacology and  
Experimental Therapeutics,  
Tufts University School of Medicine,  
136 Harrison Avenue,  
Boston, MA 02111, USA  
Phone: (617) 636-6866  
Fax: (617) 636-2456  
E-mail: theoharis.theoharis@tufts.edu

Aspects of the work discussed were supported in part by grants from US NIH #AR47652 and NS 38326. Theta Biomedical Consulting and Development Co., Inc. (Brookline, MA) TCT has been awarded US patents #5,250,529; #6,020,305; #5,648,350; #5,855,884; #5,821,259; #5,994,357; #6,624,148 covering the use of CRH and mast cell blockers in inflammatory diseases.

**TABLE 1. Mast cell Triggers**

Antigen + IgE
Anaphylatoxins
CRH
IL-1
Immunoglobulin – free light chains
LPS
NGF
NT
SCF
SP
Superantigens
Ucn
VIP
Viral DNA sequences

mune [7] or inflammatory processes [8]. Instead, mast cells can secrete mediators without overt degranulation [9], through differential or selective release [10], probably regulated by the action of distinct protein kinases on a unique phosphoprotein [11,12]. In such cases, mast cells undergo ultrastructural alterations of their electron dense granular core indicative of secretion, but without overt degranulation, a process that has been termed “activation” [13-15] “intragranular activation” [16] or “piecemeal” degranulation [17]. Selective release has been reported for a number of mediators [18-20], especially serotonin [10], eicosanoids [21-23] or IL-6 [24-27]. In fact, we showed that interleukin-1 (IL-1) can stimulate human mast cells to release IL-6 selectively without degranulation, through a unique process utilizing 40-80 nm vesicles unrelated to the secretory granules (800-1000 nm) [28]. We also recently showed that corticotropin releasing hormone (CRH) secreted under stress can stimulate human mast cells through specific CRH receptors to release vascular endothelial growth factor (VEGF) selectively [29].

These findings suggest that mast cells may also be involved in inflammatory diseases [6,30] that include migraines [31] and cardiovascular disease [32].

**2. MENINGEAL INFLAMMATION AND MIGRAINES**


Migraine headache is still a descriptive term that has been used primarily to refer to the brain and is usually associated with meningeal and cerebral vasodilation, as well as “spreading” neuronal depression [33]. It was hypothesized that mast cells may be involved in the pathophysiology of migraines [31]. Mast cells are located in close apposition to neurons in the meninges [34,35] and can be activated by neuropeptides [36], by antidromic nerve stimulation [14], as well as by acute immobilization stress [15]. Brain mast cells were also activated

by acute stress leading to increased vascular permeability [37], effects dependent on mast cells and CRH [38].

Stress is known to precipitate or exacerbate migraines, raising the possibility of some underlying pathologic mechanism. One such possibility comes from one study of children migraineurs, in whom the frequency and severity of migraines was reduced, along with the unique mast cell biochemical marker tryptase, when they were taught relaxation techniques [39]. Recent studies have shown that stress-induced neurogenic inflammation depends on NK-1 receptors, but does not require SP [40], while it may involve a direct action of CRH on brain microvessels [41]. Yet, delayed responses may also involve IL-6 and nitric oxide elevations in dura macrophages [42]. These findings have led to a new model for the pathogenesis of intracranial neurogenic inflammation (Fig. 1) that calls for hypothalamic CRH acting on the sensory nucleus of the trigeminal nerve, which has been reported to express CRH receptors [43]; CRH could then secrete mast cell stimulating peptides and/or have a direct action on mast cells and/or on the vasculature [6]. These processes have recently been reviewed [44], as has been the important role of mast cells in migraine pathophysiology [45].

**CONCLUSION**

In summary, the mast cell has emerged as a unique immune cell that could be activated by many non-immune pro-



**FIGURE 1.** Schematic representation of the sequence of events that may induce brain mast cell activation and neurogenic inflammation, leading to migraines.

TABLE 2. Mast Cell Mediators

Mediators	Main Pathophysiologic Effects
<b>Prestored</b>	
Biogenic Amines	
Histamine	Vasodilation, angiogenesis, mitogenesis, pain
5-Hydroxytryptamine (5-HT, serotonin)	Vasoconstriction, pain
Chemokines	
IL-8, MCP-1, MCP-3, MCP-4, RANTES	Chemoattraction and tissue infiltration of leukocytes
Enzymes	
Arylsulfatases	Lipid/proteoglycan hydrolysis
Carboxypeptidase A	Peptide processing
Chymase	Tissue damage, angiotensin II synthesis, cholesterol liberation
Kinogenases	Synthesis of vasodilatory kinins, pain
Phospholipases	Arachidonic acid generation
Tryptase	Tissue damage, activation of PAR, inflammation, pain
Peptides	
Corticotropin-releasing hormone (CRH)	Inflammation, vasodilation
Endorphins	Analgesia
Endothelin	Sepsis
Kinins (bradykinin)	Inflammation, pain, vasodilation
Somatostatin (SRIF)	Anti-inflammatory (?)
Substance P (SP)	Inflammation, pain
Vasoactive intestinal peptide (VIP)	Vasodilation
Urocortin	Inflammation, vasodilation
Vascular endothelial growth factor (VEGF)	Neovascularization, vasodilation
Proteoglycans	
Chondroitin sulfate	Cartilage synthesis, anti-inflammatory
Heparin	Angiogenesis, nerve growth factor stabilization
Hyaluronic acid	Connective tissue, nerve growth factor stabilization
<b>De novo synthesized</b>	
Cytokines	
Interleukins (IL)-1,2,3,4,5,6,9,10,13,16	Inflammation, leukocyte migration, pain
INF- $\gamma$ ; MIF; TNF- $\alpha$	Inflammation, leukocyte proliferation/activation
<i>Growth Factors</i>	
SCF, GM-CSF, b-FGF, NGF, VEGF	Growth of a variety of cells
Phospholipid metabolites	
Leukotriene B4 LTB4	Leukocyte chemotaxis
Leukotriene C4 (LTC4)	Vasoconstriction, pain
Platelet activating factor (PAF)	Platelet activation, vasodilation
Prostaglandin D2 (PGD2)	Bronchostriction, pain
Nitric oxide (NO)	Vasodilation

b-FGF= fibroblast growth factor, CRH= corticotropin-releasing hormone, CSF= colony stimulating factor, GM-CSF= granulocyte monocyte-colony stimulating factor, INF $\gamma$ = Interferon- $\gamma$ , MIF= macrophage inflammatory factor, NGF= nerve growth factor, SCF= Stem cell factor, SRIF= somatomedin release inhibitory factor, somatostatin, TGF- $\beta$ = transforming growth factor- $\beta$ , TNF- $\alpha$ = tumor necrosis factor- $\alpha$ , VEGF= vascular endothelial growth factor

cesses, including acute stress, 46 and could participate in a variety of inflammatory diseases including the brain [30].

**ACKNOWLEDGMENTS**

We thank Ms. Jessica Christian for her word processing skills.

## REFERENCES

1. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. Identification of a committed precursor for the mast cell lineage. *Science* 1996; 271:818-822.
2. Galli SJ. New concepts about the mast cell. *N Engl J Med* 1993; 328:257-265.
3. Kobayashi H, Ishizuka T, Okayama Y. Human mast cells and basophils as sources of cytokines. *Clin Exp Allergy* 2000; 30: 1205-1212.
4. Galli SJ, Wedemeyer J, Tsai M. Analyzing the roles of mast cells and basophils in host defense and other biological responses. *Int J Hematol* 2002; 75:363-369.
5. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Annu Rev Immunol* 2005; 23:749-786.
6. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. *J Neuroimmunol* 2004; 146:1-12.
7. Benoist C, Mathis D. Mast cells in autoimmune disease. *Nature* 2002; 420:875-878.
8. Woolley DE. The mast cell in inflammatory arthritis. *N Engl J Med* 2003; 348:1709-1711.
9. Theoharides TC, Douglas WW. Secretion in mast cells induced by calcium entrapped within phospholipid vesicles. *Science* 1978; 201:1143-1145.
10. Theoharides TC, Bondy PK, Tsakalos ND, Askenase PW. Differential release of serotonin and histamine from mast cells. *Nature* 1982; 297:229-231.
11. Theoharides TC, Sieghart W, Greengard P, Douglas WW. Antiallergic drug cromolyn may inhibit histamine secretion by regulating phosphorylation of a mast cell protein. *Science* 1980; 207:80-82.
12. Sieghart W, Theoharides TC, Alper SL, Douglas WW et al. Calcium-dependent protein phosphorylation during secretion by exocytosis in the mast cell. *Nature* 1978; 275:329-331.
13. Dimitriadou V, Lambracht-Hall M, Reichler J, Theoharides TC. Histochemical and ultrastructural characteristics of rat brain perivascular mast cells stimulated with compound 48/80 and carbachol. *Neuroscience* 1990; 39:209-224.
14. Dimitriadou V, Buzzi MG, Moskowitz MA, Theoharides TC. Trigeminal sensory fiber stimulation induces morphologic changes reflecting secretion in rat dura mast cells. *Neuroscience* 1991; 44:97-112.
15. Theoharides TC, Sant GR, El-Mansoury M, Letourneau RJ et al. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. *J Urol* 1995; 153:629-636.
16. Letourneau R, Pang X, Sant GR, Theoharides TC. Intragranular activation of bladder mast cells and their association with nerve processes in interstitial cystitis. *Br J Urol* 1996; 77:41-54.
17. Dvorak AM, McLeod RS, Onderdonk A, Monahan-Earley RA et al. Ultrastructural evidence for piecemeal and anaphylactic degranulation of human gut mucosal mast cells in vivo. *Int Arch Allergy Immunol* 1992; 99:74-83.
18. Kops SK, Van Loveren H, Rosenstein RW, Ptak W et al. Mast cell activation and vascular alterations in immediate hypersensitivity-like reactions induced by a T cell derived antigen-binding factor. *Lab Invest* 1984; 50:421-434.
19. Van Loveren H, Kops SK, Askenase PW. Different mechanisms of release of vasoactive amines by mast cells occur in T cell-dependent compared to IgE-dependent cutaneous hypersensitivity responses. *Eur J Immunol* 1984; 14:40-47.
20. Kops SK, Theoharides TC, Cronin CT, Kashgarian MG et al. Ultrastructural characteristics of rat peritoneal mast cells undergoing differential release of serotonin without histamine and without degranulation. *Cell Tissue Res* 1990; 262:415-424.
21. Benyon R, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. *Br J Pharmacol* 1989; 97:898-904.
22. Levi-Schaffer F, Shalit M. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. *Int Arch Allergy Appl Immunol* 1989; 90:352-357.
23. van Haaster CM, Engels W, Lemmens PJMR, Hornstra G et al. Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells; roles of cytosolic calcium and protein tyrosine kinases. *Biochim Biophys Acta* 1995; 1265:79-88.
24. Leal-Berumen I, Conlon P, Marshall JS. IL-6 production by rat peritoneal mast cells is not necessarily preceded by histamine release and can be induced by bacterial lipopolysaccharide. *J Immunol* 1994; 152:5468-5476.
25. Marquardt DL, Alongi JL, Walker LL. The phosphatidylinositol 3-kinase inhibitor wortmannin blocks mast cell exocytosis but not IL-6 production. *J Immunol* 1996; 156:1942-1945.
26. Gagari E, Tsai M, Lantz CS, Fox LG et al. Differential release of mast cell interleukin-6 via c-kit. *Blood* 1997; 89:2654-2663.
27. Hojo H, Sun R, Ono Y, Shishido T et al. Differential production of interleukin-6 and its close relation to liver metastasis in clones from murine P815 mastocytoma. *Cancer Lett* 1996; 108: 55-59.
28. Kandere-Grzybowska K, Letourneau R, Boucher W, Bery J et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 2003; 171:4830-4836.
29. Cao J, Papadopoulou N, Kempuraj D, Boucher WS et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol* 2005; 174:7665-7675.
30. Theoharides TC. Mast cell: a neuroimmunoendocrine master player. *Int J Tissue React* 1996; 18:1-21.
31. Theoharides TC. Mast cells and migraines. *Perspect Biol Med* 1983; 26:672-675.
32. Constantinides P. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. *Circulation* 1995; 92:1083-1088.
33. Spierings EL. Pathogenesis of the migraine attack. *Clin J Pain* 2003; 19:255-262.
34. Dimitriadou V, Aubineau P, Taxi J, Seylaz J. Ultrastructural evidence for a functional unit between nerve fibers and type II cerebral mast cells in the cerebral vascular wall. *Neuroscience* 1987; 22:621-630.

## IMMUNOLOGY OF MIGRAINE

35. Rozniecki JJ, Letourneau R, Sugiultzoglou M, Spanos C et al. Differential effect of histamine-3 receptor active agents on brain, but not peritoneal, mast cell activation. *J Pharmacol Exp Ther* 1999; 290:1427-1435.
36. Goetzl EJ, Chernov T, Renold F, Payan DG. Neuropeptide regulation of the expression of immediate hypersensitivity. *J Immunol* 1985; 135:802s-805s.
37. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA. Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. *Neuroscience* 1992; 48:187-203.
38. Esposito P, Chandler N, Kandere-Grzybowska K, Basu S et al. Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. *J Pharmacol Exp Ther* 2002; 303:1061-1066.
39. Olness K, Hall H, Rozniecki JJ, Schmidt W et al. Mast cell activation in children with migraine before and after training in self-regulation. *Headache* 1999; 39:101-107.
40. Kandere-Grzybowska K, Gheorghe D, Priller J, Esposito P et al. Stress-induced dura vascular permeability does not develop in mast cell-deficient and neurokinin-1 receptor knockout mice. *Brain Res* 2003; 980:213-220.
41. Esposito P, Basu S, Letourneau R, Jacobson S et al. Corticotropin-releasing factor (CRF) can directly affect brain microvessel endothelial cells. *Brain Res* 2003; 968:192-198.
42. Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. *Brain* 2001; 124:2490-2502.
43. Rivest S, Laflamme N, Nappi RE. Immune challenge and immobilization stress induce transcription of the gene encoding the CRF receptor in selective nuclei of the rat hypothalamus. *J Neurosci* 1995; 15:2680-2695.
44. Theoharides TC, Donelan JM, Papadopoulou N, Cao J et al. Mast cells as targets of corticotropin-releasing factor and related peptides. *Trends Pharmacol Sci* 2004; 25:563-568.
45. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. *Brain Res Rev* 2005; 49:65-76.
46. Theoharides TC. Mast cells and stress - a psychoneuroimmunological perspective. *J Clin Psychopharmacol* 2002; 22:103-108.